Search research articles
Contact Us
Filters
Showing results (301-310 of 321) with videos related to
Page
of 33
Sort By:
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
July 23, 2025
Validation of the CFAbd-Score.kid©, a Novel gastrointestinal patient reported outcome measure, specific for children with cystic fibrosis
Pauline Sadrieh, Lilith Bechinger, Franziska Duckstein, et al.
Frontiers in Pharmacology
|
June 20, 2022
Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score
Jochen G Mainz, Carlos Zagoya, Louise Polte, et al.
Frontiers in Pharmacology
|
May 19, 2023
Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score
Jochen G Mainz, Carlos Zagoya, Louise Polte, et al.
Journal of the American Chemical Society
|
March 24, 2025
Cathelicidin-BF: A Potent Antimicrobial Peptide Leveraging Charge and Phospholipid Recruitment against Multidrug-Resistant Clinical Bacterial Isolates
Evgeniy Salnikov, Morgane Adélaïde, Francisco Ramos-Martín, et al.
Metallomics : Integrated Biometal Science
|
April 13, 2024
Quest for a stable Cu-ligand complex with a high catalytic activity to produce reactive oxygen species
Merwan Bouraguba, Adeline M Schmitt, Venkata Suseela Yelisetty, et al.
Antibiotics (Basel, Switzerland)
|
January 25, 2025
Comparative Structural and Biophysical Investigation of <i>Lycosa erythrognatha</i> Toxin I (LyeTx I) and Its Analog LyeTx I-b
Amanda Neves de Souza, Gabriele de Azevedo Cardoso, Lúcio Otávio Nunes, et al.
Frontiers in Pharmacology
|
November 29, 2023
Dynamics of abdominal symptoms during the start of a new therapy with elexacaftor/tezacaftor/ivacaftor using the novel CFAbd-day2day questionnaire
Jochen G Mainz, Anton Barucha, Pu Huang, et al.
Amino Acids
|
September 9, 2015
The anti-inflammatory action of the analgesic kyotorphin neuropeptide derivatives: insights of a lipid-mediated mechanism
Katia Conceição, Pedro R Magalhães, Sara R R Campos, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 30, 2020
Two distinct amphipathic peptide antibiotics with systemic efficacy
Jayaram Lakshmaiah Narayana, Biswajit Mishra, Tamara Lushnikova, et al.
The Journal of Biological Chemistry
|
November 6, 2008
Structural determinants of antimicrobial and antiplasmodial activity and selectivity in histidine-rich amphipathic cationic peptides
A James Mason, Wardi Moussaoui, Tamer Abdelrahman, et al.
Page
of 33
Search research articles
Search
Showing results (301-310 of 321) with videos related to
Sort By:
Page
of 33
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
July 23, 2025
Validation of the CFAbd-Score.kid©, a Novel gastrointestinal patient reported outcome measure, specific for children with cystic fibrosis
Pauline Sadrieh, Lilith Bechinger, Franziska Duckstein, et al.
Frontiers in Pharmacology
|
June 20, 2022
Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score
Jochen G Mainz, Carlos Zagoya, Louise Polte, et al.
Frontiers in Pharmacology
|
May 19, 2023
Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score
Jochen G Mainz, Carlos Zagoya, Louise Polte, et al.
Journal of the American Chemical Society
|
March 24, 2025
Cathelicidin-BF: A Potent Antimicrobial Peptide Leveraging Charge and Phospholipid Recruitment against Multidrug-Resistant Clinical Bacterial Isolates
Evgeniy Salnikov, Morgane Adélaïde, Francisco Ramos-Martín, et al.
Metallomics : Integrated Biometal Science
|
April 13, 2024
Quest for a stable Cu-ligand complex with a high catalytic activity to produce reactive oxygen species
Merwan Bouraguba, Adeline M Schmitt, Venkata Suseela Yelisetty, et al.
Antibiotics (Basel, Switzerland)
|
January 25, 2025
Comparative Structural and Biophysical Investigation of <i>Lycosa erythrognatha</i> Toxin I (LyeTx I) and Its Analog LyeTx I-b
Amanda Neves de Souza, Gabriele de Azevedo Cardoso, Lúcio Otávio Nunes, et al.
Frontiers in Pharmacology
|
November 29, 2023
Dynamics of abdominal symptoms during the start of a new therapy with elexacaftor/tezacaftor/ivacaftor using the novel CFAbd-day2day questionnaire
Jochen G Mainz, Anton Barucha, Pu Huang, et al.
Amino Acids
|
September 9, 2015
The anti-inflammatory action of the analgesic kyotorphin neuropeptide derivatives: insights of a lipid-mediated mechanism
Katia Conceição, Pedro R Magalhães, Sara R R Campos, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 30, 2020
Two distinct amphipathic peptide antibiotics with systemic efficacy
Jayaram Lakshmaiah Narayana, Biswajit Mishra, Tamara Lushnikova, et al.
The Journal of Biological Chemistry
|
November 6, 2008
Structural determinants of antimicrobial and antiplasmodial activity and selectivity in histidine-rich amphipathic cationic peptides
A James Mason, Wardi Moussaoui, Tamer Abdelrahman, et al.
Page
of 33